CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Angiotensin–neprilysin inhibition versus enalapril in heart failure A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Heart Failure With Preserved Ejection Fraction in the Young The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society The Hospital Readmissions Reduction Program Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report

Clinical Trial2014 Sep 11;371(11):993-1004.

JOURNAL:N Engl J Med. Article Link

Angiotensin–neprilysin inhibition versus enalapril in heart failure

McMurray JJ, Packer M, PARADIGM-HF Investigators and Committees. Keywords: angiotensin receptor-neprilysin inhibitor LCZ696; enalapril; HFrEF; mortality; survival; hospitalization for heart failure

FULL TEXT PDF